Loading
A phase 3 trial of Efbemalenograstim alfa and Filgrastim in Breast cancer, run by EVIVE Biotechnology, completed.
Study to Compare the Efficacy and Safety of F-627 and GRAN® is a phase 3 interventional study registered as NCT04174599 by EVIVE Biotechnology, with 242 participants recorded, started 2018-04-12 and reaching its primary completion in 2019-01-24. Interventions recorded: F-627, GRAN®. Conditions recorded: Breast Cancer, Neutropenia.
Linked to the drug Efbemalenograstim alfa because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
242 enrolled.
SD 1.100; Figures from the ClinicalTrials.gov results section (first posted 2025-04-20), not from a publication · SD 0.967
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Duration of Grade 3 or 4 Neutropenia (ANC <1.0×10^9/L) in Cycle 1primary | F-627 | 120 | 0.68 days | - | - | link |
| GRAN® | 119 | 0.71 days |
Shares Evive Biotech, Efbemalenograstim alfa, Breast cancer (all types) and the tag pipeline.
Shares Evive Biotech, Efbemalenograstim alfa, Breast cancer (all types) and the tag pipeline.
Shares Filgrastim (G-CSF), Breast cancer (all types) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.